Clinical Trials Browser

NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Phase 1 Terminated

4 enrolled 11 charts

Breast

Breast Neoplasms

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Phase 2 Terminated

65 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT01897441 2024-12-24

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Phase NA Terminated

31 enrolled 11 charts

Breast

Breast Neoplasms

NCT04190056 2023-08-31

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Phase 2 Terminated

1 enrolled 4 charts

Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast

Breast Neoplasms

NCT02936206 2021-05-19

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Phase 1 Terminated

2 enrolled 5 charts

Breast

Breast Neoplasms

NCT02395627 2020-07-07

Reversing Therapy Resistance With Epigenetic-Immune Modification

Phase 2 Terminated

38 enrolled 18 charts

Breast

Breast Neoplasms

NCT00096369 2019-01-24

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

Phase 2 Terminated

130 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT00873366 2018-01-23

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

Terminated

92 enrolled 20 charts

Breast

Breast Neoplasms

NCT00290654 2017-12-28

Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

Phase 2 Terminated

45 enrolled 11 charts

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Phase 2/3 Terminated

10 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00206492 2017-08-01

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Phase 2 Terminated

3 enrolled

Breast

Breast Neoplasms, Neoplasms

NCT00899197 2017-08-01

Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Terminated

2 enrolled

Breast

Breast Neoplasms

NCT02322853 2017-05-24

OLYMPE

Phase 2 Terminated

8 enrolled

Breast

Breast Neoplasms

NCT02089386 2017-03-13

Tamoxifen to Treat Barrett's Metaplasia

Phase EARLY_PHASE1 Terminated

7 enrolled

Gastrointestinal

Barrett Esophagus

NCT01194908 2015-01-26

Re-expression of ER in Triple Negative Breast Cancers

Phase 1/2 Terminated

5 enrolled 5 charts

Breast

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast

Breast Neoplasms

NCT00183963 2014-05-22

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Phase 2 Terminated

4 enrolled 8 charts

Breast

Breast Neoplasms

NCT01194427 2013-05-17

A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer

Phase 2 Terminated

2 enrolled 3 charts

Breast

Breast Neoplasms

NCT00210028 2006-11-14

Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer

Phase 2 Terminated

40 enrolled

Breast

Breast Neoplasms